Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets
Devaraj Ezhilarasan a,∗, Etienne Sokal b, Mustapha Najimi b
a Biomedical Research Unit and Laboratory Animal Centre, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences,
Chennai 600 077, Tamil Nadu, India
b Institut de Recherche Expérimentale et Clinique (IREC), Laboratory of Pediatric Hepatology and Cell Therapy, Université Catholique de Louvain, Brussels
1200, Belgium ∗ Corresponding author.
E-mail address: ezhild@gmail.com (D. Ezhilarasan).
Abstract：Hepatic fibrosis is a pathological lesion, characterized by the progressive accumulation of extracellular matrix (ECM) in the perisinusoidal space and it is a major problem in chronic liver diseases. Phenotypic activation of hepatic stellate cells (HSC) plays a central role in the progression of hepatic fibrosis. Retardation of proliferation and clearance of activated HSCs from the injured liver is an appropriate therapeutic strategy for the resolution and treatment of hepatic fibrosis. Clearance of activated HSCs from the injured liver by autophagy inhibitors, proapoptotic agents and senescence inducers with the high affinity toward the activated HSCs may be the novel therapeutic strategy for the treatment of hepatic fibrosis in the near future.
. [J]. Hepatobiliary Pancreat Dis Int, 2018, 17(3): 192-197.
Ezhilarasan D, Sokal E, Najimi M. Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets. Hepatobiliary Pancreat Dis Int, 2018, 17(3): 192-197.
2018, Vol. 17 
